Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.3
2.8
Journals
Current Oncology
Special Issues
Gastrointestinal Cancers in Eastern Canada
share announcement

Gastrointestinal Cancers in Eastern Canada

A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Gastrointestinal Oncology".

Deadline for manuscript submissions: closed (31 December 2024) | Viewed by 1396

Special Issue Editor

Dr. Timothy Asmis

E-Mail Website
Guest Editor
Division of Medical Oncology, Department of Medicine, The Ottawa Hospital Cancer Center and the University of Ottawa, Ottawa, ON K1N 6N5, Canada
Interests: gastrointestinal cancers; sarcoma

Special Issue Information

Dear Colleagues,

Gastrointestinal (GI) cancers are a leading cause of mortality and morbidity amongst Canadians. According to the Canadian Cancer Statistics, the proportion of prevalent cancer cases, as well as the incidence of cancer, is the highest in Canada’s Eastern Provinces. For the last 20 years, clinicians who treat GI cancers have met annually at the Eastern Canadian Gastrointestinal Cancer Consensus Conference (GI EC4) to review the latest evidence around the treatment of GI cancers and have developed evidence-based consensus guidelines.  These guidelines have been particularly useful in guiding the management of patients with GI cancers, and provide key information to policy makers, provincial governments, and other stakeholders. Clinicians and researchers who treat and study patients with GI cancers in Eastern Canada are uniquely positioned to address the challenges arising in these jurisdictions. As a result, their perspectives are critical in developing the GI EC4 guidelines and improving cancer care for patients in Eastern Canada.

This Special Issue aims to expand our knowledge on gastrointestinal cancers that affect patients in Eastern Canada.

Current Oncology is an international, peer-reviewed open access journal on oncology. This Special Issue invites a range of papers from original research articles to comprehensive reviews on THE incidence, prevalence, prevention, screening and treatment of the gastrointestinal cancers that affect patients in Eastern Canada.

We welcome manuscripts in the following formats:

  • Original research;
  • Review articles;
  • Short communications.

I look forward to receiving your contributions.

Dr. Timothy Asmis
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • colorectal cancer
  • hepatocellular carcinoma
  • Eastern Canada
  • gastric cancer
  • gastrointestinal cancers
  • rectal cancer
  • biliary tract cancer
  • cholangiocarcinoma gastroesophageal cancer

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

10 pages, 805 KiB  
Article
Treatment Patterns of Pancreatic Neuroendocrine Tumor (pNET) Patients at Two Canadian Cancer Centres
by Gautham Nair, Morgan Black, Kathie Baer, Stephen Welch, David T. Laidley, Rachel Goodwin, Macyn Leung, William J. Phillips, Michael Vickers, Tim Asmis, Horia Marginean and Elena Tsvetkova
Curr. Oncol. 2025, 32(2), 86; https://doi.org/10.3390/curroncol32020086 (registering DOI) - 3 Feb 2025
Abstract
Pancreatic neuroendocrine tumors (pNETs) are rare but increasingly prevalent malignancies with varied prognoses and a diverse range of treatment options, including surgery, somatostatin analogues (SSAs), chemotherapy, targeted therapy, and peptide receptor radionuclide therapy (PRRT). This retrospective cohort study analyzed treatment patterns among 189 [...] Read more.
Pancreatic neuroendocrine tumors (pNETs) are rare but increasingly prevalent malignancies with varied prognoses and a diverse range of treatment options, including surgery, somatostatin analogues (SSAs), chemotherapy, targeted therapy, and peptide receptor radionuclide therapy (PRRT). This retrospective cohort study analyzed treatment patterns among 189 pNET patients treated between January 2010 and June 2021 at two Canadian cancer centres: the Verspeeten Family Cancer Centre (VFCC), which offers PRRT, and the Ottawa Hospital Cancer Centre (TOHCC), which does not at the time of the study. Data on demographics, tumor characteristics, and treatment modalities were collected, and statistical analyses were conducted using chi-square, Fisher’s exact test, and the Kruskal–Wallis test. Among eligible patients, 53% presented with stage IV disease. Surgical resection was the most common treatment, followed by SSAs, chemotherapy, PRRT, and targeted therapy. Stage IV patients at VFCC were significantly more likely to receive PRRT (60%) compared to TOHCC (6%) and underwent more PRRT cycles, with a higher prevalence of well-differentiated tumors observed at VFCC. With these differences it was clear that the non-PRRT centre was unable to provide patients with the same level of PRRT access during the study period compared to patients seen at the PRRT site. The findings underscore the critical role of PRRT availability in influencing treatment patterns and highlight the need for equitable access to specialized therapies across Canada to optimize outcomes for pNET patients. Full article
(This article belongs to the Special Issue Gastrointestinal Cancers in Eastern Canada)
►▼ Show Figures

Figure 1

12 pages, 787 KiB  
Article
Implementation of a Hepatitis B Screening Program in Patients Receiving Systemic Anti-Cancer Therapy
by Jennifer Leigh, Ranjeeta Mallick, Stephanie Brule, Lisa Rambout, Jennifer Newton, Dominick Bossé, Curtis Cooper and Joanna Gotfrit
Curr. Oncol. 2025, 32(1), 20; https://doi.org/10.3390/curroncol32010020 - 30 Dec 2024
Viewed by 709
Abstract
Cancer patients receiving non-endocrine therapies are at risk of hepatitis B virus (HBV) reactivation (HBVr). Guidelines recommend HBV screening prior to treatment. The Ottawa Hospital Cancer Center implemented a screening pilot for all patients receiving FOLFOX-based regimens between January and April 2023. We [...] Read more.
Cancer patients receiving non-endocrine therapies are at risk of hepatitis B virus (HBV) reactivation (HBVr). Guidelines recommend HBV screening prior to treatment. The Ottawa Hospital Cancer Center implemented a screening pilot for all patients receiving FOLFOX-based regimens between January and April 2023. We assessed the pilot from a quality improvement perspective. Charts were retrospectively reviewed, and patient and disease characteristics were collected. The primary endpoint was to identify the proportion of patients who underwent HBV screening prior to treatment start. Univariate analyses assessed the association between baseline characteristics and failure to screen. Quality metrics were also reviewed. There were 32/42 patients (76.2%) who completed screening, and 5 (11.9%) had a positive screen. The majority of eligible patients (59.5%) completed screening prior to the first treatment as intended. Four of five patients who tested positive were referred to Infectious Diseases. Of those, one received antivirals for chronic HBV. There were no treatment delays due to pending screening and no HBV reactivation. Receipt of prior systemic therapy was significantly associated with failure to screen (55 vs. 95%, OR 17.1 (95% CI 1.92–153), p = 0.011). The results of this pilot highlight the importance of building HBV screening into standardized treatment plans and engaging all team members to ensure high levels of screening. Prior systemic therapy receipt was associated with failure to screen, and thus, programs should include education on the necessity of screening as recommended by medical guidelines. Full article
(This article belongs to the Special Issue Gastrointestinal Cancers in Eastern Canada)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop